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ABSTRACT 36 
Objectives: To examine outcome reporting bias of systematic reviews registered in PROSPERO. 37 
Study Design and Setting: Retrospective cohort study. The primary outcomes from systematic 38 
review publications were compared with those reported in the corresponding PROSPERO 39 
records; discrepancies in the primary outcomes were assessed as upgrades, additions, omissions 40 
or downgrades. Relative risks (RR) and 95% confidence intervals (CI) were calculated to 41 
determine the likelihood of having a change in primary outcome when the meta-analysis result 42 
was favourable and statistically significant.  43 
Results: 96 systematic reviews were published. A discrepancy in the primary outcome occurred 44 
in 32% of the included reviews and 39% of the reviews did not explicitly specify a primary 45 
outcome(s); 6% of the primary outcomes were omitted. There was no significant increased risk 46 
of adding/upgrading (RR 2.14, 95% CI 0.53 to 8.63) or decreased risk of downgrading (RR 0.76, 47 
0.27-2.17) an outcome when the meta-analysis result was favourable and statistically significant. 48 
As well, there was no significant increased risk of adding/upgrading (RR 0.89, 0.31-2.53) or 49 
decreased risk of downgrading (RR 0.56, 0.29-1.08) an outcome when the conclusion was 50 
positive. 51 
Conclusions: We recommend review authors carefully consider primary outcome selection and 52 
journals are encouraged to focus acceptance on registered systematic reviews.  53 
 54 
Word count: 200 (abstract), 3286 (main text), 2 figures, 3 tables, 14 appendices.  55 
Keywords: bias, methodology, quality, reporting, systematic reviews, outcome reporting bias 56 
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Running title: Examining outcome reporting bias in systematic reviews  57 
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What is new? 
Key finding 
• Many systematic reviews that are registered in PROSPERO have discrepancies in primary 
outcomes between their record and review publication. 
What this study adds to what is known? 
• This is the first study to examine outcome reporting bias using the PROSPERO register, a 
database for prospectively registering systematic reviews that was established in 2011.  
• Previous studies have compared outcomes reported in Cochrane reviews to those reported in 
the corresponding review protocols. These studies found that more than 1/3 of published 
systematic reviews had a discrepancy between the outcomes reported in the protocol versus 
final publication. One study found evidence of outcome reporting bias, in which statistically 
significant outcomes were more likely to be upgraded (i.e. promoted from secondary to 
primary) or added in the final publication compared to the protocol.  
• We found that approximately 1/3 of published systematic reviews had a discrepancy 
between the outcomes reported in the PROSPERO record versus the review publication. 
However, evidence of outcome reporting bias was not observed.  
What is the implication, and what should change now? 
• Our study suggests that non-Cochrane review authors have similar outcome reporting 
behaviours to Cochrane review authors. We recommend that all non-Cochrane reviews are 
registered with PROSPERO, review authors carefully consider the selection of primary 
outcomes, peer reviewers should check PROSPERO to see if there are any discrepancies 
between the record and review publication, and journals are encouraged to focus acceptance 
on registered systematic reviews. 
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1. INTRODUCTION 58 
The Cochrane Handbook for Systematic Reviews of Interventions [1] states that 59 
systematic reviewers should prepare a systematic review protocol prior to their review conduct, 60 
to encourage transparency of reporting hypotheses and methods (including outcomes) and avoid 61 
outcome reporting bias. This is consistent with the Institute of Medicine Standards for 62 
Systematic Reviews [2]. As well, the Cochrane Handbook [1] and Preferred Reporting Items for 63 
Systematic reviews and Meta-Analyses Statement [3] state that any changes to the protocol 64 
should be fully documented and explained in the systematic review publication. Despite this 65 
guidance, research consistently has found that more than 1/3 of published systematic reviews 66 
have an undisclosed discrepancy between the outcomes reported in the protocol versus final 67 
review [4-7].  68 
In the most simplistic definition, outcome reporting bias “occurs when a study in which 69 
multiple outcomes were measured reports only those that are [statistically] significant” [8]. 70 
Previous studies have compared final Cochrane review methods to those reported in the review 71 
protocols [4-7], including a recent Cochrane methodology review on outcome reporting bias [9]. 72 
One of these studies found evidence of outcome reporting bias, in which statistically significant 73 
outcomes were more likely to be upgraded (i.e. promoted from secondary to primary) or added in 74 
the final publication compared to the protocol [5]. All of these studies included a sample of 75 
systematic reviews published in the Cochrane Database of Systematic Reviews prior to the year 76 
2009. 77 
The International Prospective Register of Systematic Reviews (PROSPERO) was 78 
established in 2011 [10] and is the only open access online facility to prospectively register non-79 
Cochrane systematic reviews. Since most published systematic reviews are not Cochrane reviews 80 
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[11], this register of review protocol details is likely a more representative sample of systematic 81 
reviews in the literature. No previous study has explored outcome reporting bias of systematic 82 
reviews registered in PROSPERO. As such, we aimed to 1) examine whether outcome reporting 83 
bias exists, and to what extent, in published systematic reviews registered in PROSPERO, as 84 
well as 2) assess the methodological quality of published systematic reviews that were registered 85 
in PROSPERO.  86 
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2. METHODS 87 
2.1 Protocol 88 
Prior to conducting this retrospective cohort study, we created a project plan, which 89 
outlined our study methods. Our protocol was revised after receiving feedback from all authors. 90 
The final protocol can be found in Appendix A. Since this study was not a systematic review, it 91 
was not eligible to be registered with the PROSPERO repository. 92 
2.2 Sample of systematic reviews 93 
We aimed to identify all completed systematic reviews of interventions that were 94 
registered in PROSPERO. On November 29, 2013, all records from the PROSPERO database 95 
identified as “Completed and Published” were downloaded. These records also include the 96 
citation/link to the final publication. PROSPERO includes an audit trail for protocol amendments 97 
and progress reports. For the purpose of our study, the protocol record used was the version 98 
immediately prior to the version where the Named Contact updated the record to report that the 99 
review had been completed. Our scope was limited to systematic reviews of interventions to 100 
allow the comparison of statistically significant meta-analysis results, which would not be 101 
feasible for other review products (e.g., diagnostic reviews, prognostic reviews, prevalence 102 
reviews). Only non-Cochrane reviews were included. Completed reviews not published in 103 
English were also excluded, due to resource limitations.  104 
2.3 Data abstraction process 105 
A data abstraction form with an explanation guide was developed (Appendix Table A) 106 
and calibrated through a team exercise. Specifically, the team independently pilot-tested the 107 
forms using a random sample of 10 included systematic reviews. Data abstraction did not 108 
commence until high agreement (>90%) was achieved. Subsequently, 3 pairs of reviewers 109 
abstracted each of the systematic review publications, independently. In order to ensure 110 
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consistency across the team regarding the classification of outcomes, one team member verified 111 
all of the data (EC) and resolved discrepancies.  112 
2.4 Data items 113 
The data items were abstracted from both the protocol details and the publication, and 114 
included study characteristics (e.g., year of publication, number of studies included, type of 115 
studies included, whether meta-analysis was conducted, source of funding), number of primary 116 
outcomes, changes in primary outcomes from the PROSPERO record to review publication, 117 
reasons for changes in primary outcomes (if reported), meta-analysis results, and conclusions. 118 
The reason we focused on primary outcomes is because this is the outcome of greatest interest 119 
and importance. Similar research on outcome reporting bias has used this approach [4-7].  120 
If the primary outcome(s) was not explicitly stated in the publication (i.e. not specifically 121 
called a “primary” outcome), the following decision-tree approach [12, 13] was used to “derive” 122 
the primary outcome(s), by selecting the outcome that met the first of the following criteria: (1) 123 
the outcome(s) listed in the title; (2) the outcome(s) listed in the objectives; (3) the most serious 124 
outcome (e.g., mortality). To facilitate comparison across studies, all changes in primary 125 
outcomes from the PROSPERO record to the systematic review publication were coded using 126 
the same classification scheme used in the Parmelli et al. [7] and Kirkham et al. [5] studies. 127 
These categories were new inclusion of outcomes (or additions), exclusion, upgrade, and 128 
downgrade of outcomes (Box). The meta-analysis results were categorized using a previous 129 
approach [13], including favourable and statistically significant, favourable and not statistically 130 
significant, neutral, unfavourable and not statistically significant, and unfavourable and 131 
statistically significant (Box, Appendix Figure A). The conclusions were obtained from the 132 
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abstract and discussion sections from the systematic reviews and were categorized using a 133 
previous approach [13], including positive, neutral, negative, and indeterminate (Box). 134 
We used the same hierarchy reported by Kirkham et al. to select meta-analyses from 135 
systematic reviews with multiple treatment group comparisons [5]. Specifically, we selected the 136 
first intervention comparison which met the following criteria: “(1) an intervention comparison 137 
described in the protocol as the primary review comparison; (2) the first intervention comparison 138 
mentioned in the title of the protocol; (3) an intervention comparison described in the review as 139 
the primary review comparison; (4) the first intervention comparison mentioned in the objectives 140 
of the review; (5) the intervention comparison used in the first meta-analysis presented in the 141 
review.”  142 
2.5Methodological quality appraisal 143 
The overall methodological quality of the systematic reviews was assessed using the 144 
Assessment of Multiple SysTemAtic Reviews (A STAR) tool (Appendix Table B) [14]. The 145 
scores range from 0 to 11, with higher scores indicating superior quality. For our study, a score 146 
of 8 or higher was considered higher quality. This assessment was conducted to ascertain the 147 
overall quality of completed and published systematic reviews that were registered in 148 
PROSPERO. 149 
2.6 Analysis 150 
We explored the association between statistical significance of meta-analysis results and 151 
adding, upgrading or downgrading of outcomes compared to no discrepancies, by calculating a 152 
relative risk (RR) and 95% confidence interval (CI), where the meta-analysis results were 153 
dichotomised into favourable and statistically significant versus any of the other 4 categories. 154 
The formula is RR=[a/(a+b)]÷[c/(c+d)], where a is the number of meta-analysis outcomes that 155 
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are discrepant and have a favourable and statistically significant result, b is the number of meta-156 
analysis outcomes that are not discrepant and have a favourable and statistically significant 157 
result, c is the number of meta-analysis outcomes that are discrepant and do not have a 158 
favourable and statistically significant result, and d is the number of meta-analysis outcomes that 159 
are not discrepant and do not have favourable and statistically significant result. This analysis 160 
was similar to those conducted by Page and colleagues in their Cochrane review of outcome 161 
reporting bias [9]. The RR and 95% CI were calculated for outcomes that were explicitly 162 
reported as primary outcomes, as well as including those that were derived using the 163 
classification scheme reported above. Our hypotheses were that when the meta-analysis result 164 
was favourable and statistically significant, adding/upgrading of outcomes would be more likely 165 
while downgrading of outcomes would be less likely. A sensitivity analysis was also conducted 166 
consistent with the analysis method used by Kirkham and colleagues [5], to allow comparability 167 
of results. For this analysis, the meta-analysis results were dichotomised into statistically 168 
significant versus not statistically significant and the hypotheses were that new/upgraded 169 
outcomes would be more likely to have statistically significant meta-analysis results while 170 
downgraded outcomes would be less likely, than if there was no discrepancy.  171 
We also conducted a post-hoc analysis for systematic reviews that were funded. Similar 172 
to our primary analysis, we explored the association between statistical significance of meta-173 
analysis results and adding, upgrading or downgrading of outcomes compared to no 174 
discrepancies by calculating a RR and 95% CI, where the meta-analysis results were 175 
dichotomised into favourable and statistically significant versus any of the other 4 categories. 176 
This analysis was repeated for systematic reviews that did not have funding. Sensitivity analyses 177 
were also conducted using the Kirkham et al. approach [5].  178 
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The RR and 95% CI were calculated for obtaining a positive conclusion for new primary 179 
outcomes or upgrades, and downgrades compared to no discrepancies (where conclusions were 180 
categorised as positive versus all other conclusion types). Our hypotheses were that when the 181 
conclusion was positive, adding/upgrading of outcomes would be more likely while 182 
downgrading of outcomes would be less likely. A sensitivity analysis was also conducted to 183 
calculate the RR and 95% CI using a similar approach as to Kirkham et al. [5]. For this 184 
sensitivity analysis, our hypothesis was that when outcomes were added or upgraded, a positive 185 
conclusion would be more likely, while when outcomes were downgraded, a positive conclusion 186 
would be less likely.   187 
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3. RESULTS 188 
3.1 Sample of PROSPERO records  189 
In November 2013, 2,426 protocol records were registered with PROSPERO and 344 190 
were completed systematic reviews (Figure 1). Of the completed reviews, 140 were potentially 191 
relevant (i.e., published or in press), and of these 44 were excluded because they were not 192 
systematic reviews of interventions or the final review was not written in English (Appendix 193 
Table C). Ninety-six systematic reviews fulfilled the eligibility criteria and were subsequently 194 
included (Appendix Table C).  195 
3.2 Systematic review characteristics  196 
Eighty-nine (92.7%) of the systematic reviews were published between 2012 and 2013, 197 
and 4 (4.2%) were published in 2014, as they were in press at the time we downloaded their 198 
PROSPERO records. 81 (84.3%) included 2 to 30 studies, 56 (58.3%) limited inclusion to 199 
randomized controlled trials, and 67 (68.8%) conducted a meta-analysis (Table 1). In addition, 200 
36 (37.5%) reported no source of funding, 45 (46.9%) were conducted in the United Kingdom or 201 
North America, and 5 (5.2%) published their protocol in a journal.  202 
3.3 Methodological quality 203 
 Eight of the 11 AMSTAR items were adequately addressed by more than 72 (75%) of the 204 
systematic reviews (Figure 2, Appendix Table D). However, 72 (75%) of the reviews did not 205 
state conflicts of interest for included studies and review authors, 63 (66%) did not provide a list 206 
of excluded studies, 39 (41%) did not assess publication bias where it would have been 207 
appropriate to do so, and 14 (15%) did not consider methodological quality or risk of bias results 208 
in their conclusion statements.  209 
3.4 Outcome reporting 210 
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Although the primary outcome was indicated in PROSPERO, which is structured to 211 
separate primary and secondary outcomes, it was not explicitly reported for 37 (38.5%) of the 212 
completed systematic reviews, so was derived for the purpose of our study (Table 2). The 213 
primary outcomes were derived using the title (35.2%), objectives (24.3%), or were the most 214 
serious outcomes (40.5%). Thirty-one (32.3%) of the systematic reviews had a discrepancy 215 
between the primary outcomes reported in the PROSPERO record and final publication, while 65 216 
(67.7%) had no discrepancies (Table 3). Of the reviews with discrepancies, 6 (5.9%) had a new 217 
primary outcome, 6 (5.9%) excluded a primary outcome, 6 (5.9%) upgraded an outcome, and 22 218 
(21.8%) downgraded a primary outcome. One (1.0%) of the systematic reviews reported a reason 219 
for changing their primary outcome. Six (5.9%) systematic reviews reported a change in their 220 
primary outcome definition and 1 (1.0%) changed the measurement method for the primary 221 
outcome.  222 
3.5 Meta-analysis results 223 
The results of 139 meta-analyses in 67 systematic reviews are presented in Appendix 224 
Table E. There was no significant increased risk of adding or upgrading an outcome when the 225 
meta-analysis result was favourable and statistically significant (RR 2.14, 95% CI 0.53 to 8.63), 226 
which was the same result as found in our sensitivity analysis (Appendix Table F). This result 227 
was unchanged when only the primary outcomes that were explicitly reported were included in 228 
our analysis (RR 2.02, 95% CI 0.35 to 11.56; Appendix Table G). Further, there was no 229 
significant decreased risk of downgrading an outcome when the meta-analysis result was 230 
favourable and statistically significant (RR 0.76, 95% CI 0.27 to 2.17) and the same result was 231 
observed in our sensitivity analysis. Similarly, when only the primary outcomes that were 232 
explicitly reported were included in our analysis, no statistically significant results were 233 
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observed for downgrades (RR 1.37, 95% CI 0.20 to 9.42). Calculations were not possible for 234 
excluded primary outcomes since they were absent from the publications (by definition). 235 
 A post-hoc analysis was conducted for systematic reviews with funding, as well as for 236 
systematic reviews without funding (Appendix Tables H-J). No statistically significant results 237 
were observed in our overall analysis or sensitivity analyses.  238 
3.6 Conclusion statements 239 
The categorisation of conclusions for all included systematic reviews is presented in 240 
Appendix Table K. There was no significant increased risk of adding or upgrading outcomes 241 
when the conclusion was positive (RR 0.89, 95% CI 0.31 to 2.53). Further, there was no 242 
significant decreased risk of downgrading an outcome when the conclusion was positive (RR 243 
0.56, 95% CI 0.29 to 1.08). Our sensitivity analyses also found no significant risk of a positive 244 
conclusion when the outcomes were added/upgraded or downgraded (Appendix Table L).  245 
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4. DISCUSSION  246 
One-third of published systematic reviews that were registered with PROSPERO had a 247 
discrepancy between the primary outcome reported in their record and the primary outcome 248 
reported in the review publication. Of the discrepancies, downgrading of primary outcomes was 249 
most common (22%), and 6% of reviews omitted a protocol-specified primary outcome from the 250 
review. In addition, 39% of reviews did not explicitly specify a primary outcome(s) in the 251 
review. Although a lot of discrepancies were observed, we did not find statistically significant 252 
associations between discrepant outcome reporting and having a favourable and statistically 253 
significant meta-analysis result or positive conclusion. However, the small number of reviews 254 
within each subgroup of discrepancy classification likely limited the statistical power to detect 255 
statistically significant results. PROSPERO has now passed 5,000 registrants and repeating this 256 
study is likely to yield a larger number of published systematic reviews to examine.  257 
Our study is the first to measure outcome reporting bias of systematic reviews that were 258 
registered in PROSPERO. To examine this issue, we systematically searched for 96 systematic 259 
reviews published between 2011 and 2014. We abstracted data in duplicate, which were triple-260 
checked by a third reviewer, and appraised the included reviews using the AMSTAR tool. The 261 
included systematic reviews were of high methodological quality, on average. Areas for 262 
improvement included providing a list of excluded studies, assessing publication bias when 263 
appropriate (as per the AMSTAR criterion), and reporting conflicts of interest for the systematic 264 
review authors, as well as for the included studies. 265 
Our results are only generalizable to intervention reviews, as the risk of outcome 266 
reporting bias in other types of reviews (e.g., diagnostic reviews) remains unknown. As well, we 267 
only included non-Cochrane reviews. We considered only primary outcomes, which may have 268 
underestimated the occurrence of outcome reporting bias for all types of outcomes. However, 269 
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this is the same approach to other studies examining outcome reporting bias [4-7]. Limited 270 
resources meant that we were unable to contact authors of the discrepant systematic reviews to 271 
determine the reason for these inconsistencies. Only one review reported a rationale for changing 272 
the outcome, which makes it difficult to provide definitive conclusions as to why these changes 273 
may occur [15]. The reason that was reported by the authors was that the clinical experts on their 274 
team selected the most clinically important outcomes, which did not align with what was 275 
reported in their PROSPERO record. We were unable to include a larger sample of published 276 
and completed systematic reviews, due to resource restraints. Due to the small number of 277 
included reviews in our analyses, we were unable to examine possible sources of heterogeneity 278 
that may have confounded our results or conduct sub-group analysis for outcome reporting bias 279 
for systematic reviews with active comparators versus placebo, “high” versus “low” quality as 280 
per the AMSTAR tool, and randomized trials versus non-randomized studies. As well, there is a 281 
chance that there were more completed systematic reviews that were published but the authors of 282 
the review failed to update their PROSPERO record (although they are sent 3auto- reminders to 283 
update their information in PROSPERO). We were only able to include the systematic reviews 284 
with meta-analyses in our statistical analysis of outcome reporting bias, which is consistent with 285 
previous studies [4-7]. Finally, we calculated risk ratios instead of odds ratios to compare our 286 
study with previous studies conducted in this area. 287 
A recent Cochrane review [9] included 4 previous studies that examined discrepancies in 288 
outcome reporting between systematic review protocols and published systematic reviews [4-7]. 289 
All of these studies included Cochrane reviews that were published between 2000 and 2009 and 290 
none appraised the methodological quality of included systematic reviews using the AMSTAR 291 
tool. A total of 485 Cochrane Reviews were included and discrepancies were identified in 38% 292 
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of these. A meta-analysis of two of the studies was conducted and no statistically significant 293 
association between statistical significance of meta-analysis results and discrepant outcome 294 
reporting (adding, upgrading or downgrading) was found. These results are consistent with those 295 
observed in our study. 296 
Our results suggest that authors of non-Cochrane reviews are similar to Cochrane review 297 
authors in their outcome reporting behaviours. It is possible that systematic review authors are 298 
not focused on identifying primary outcomes of interest at the protocol stage, and are instead just 299 
completing the PROSPERO form. Further, as registration in PROSPERO is voluntary (and is 300 
relatively new) it is possible that our sample (as well as studies using samples of Cochrane 301 
reviews) underestimated the overall number of primary outcome discrepancies in systematic 302 
reviews in general.  303 
Using pre-established methods [16], we estimate that 17,399 systematic reviews were 304 
published in 2013. During this time, 1,612 Cochrane reviews were registered and 1,526 non-305 
Cochrane reviews were registered with PROSPERO. This means that only 18% of published 306 
systematic review authors registered their protocol. As such, we recommend that all non-307 
Cochrane reviews are registered with PROSPERO. Furthermore, review authors are advised to 308 
consider the selection of primary outcomes carefully and report the explanations for protocol 309 
modifications in the final review publication. Review authors should think about the importance 310 
of outcomes prior to embarking on their review and limit the number of outcomes to ensure that 311 
those selected are both necessary and meaningful. Core outcome sets have been recommended 312 
for trials (COMET initiative, http://www.comet-initiative.org/) and it is recommended that 313 
systematic review authors are familiar with this guidance when selecting outcomes for inclusion 314 
in their review. Peer reviewers should check PROSPERO to see if there are any discrepancies 315 
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between the record and review publication and ensure that the author explains these. Finally, 316 
journals are encouraged to focus acceptance on registered systematic reviews, as we found that 317 
these are likely to be of high methodological quality.  318 
 Few studies have examined outcome reporting bias in systematic reviews [9]. There has 319 
been no study of systematic reviews that are not registered with the Cochrane Collaboration or 320 
PROSPERO. This could be done by contacting review authors to obtain their unpublished 321 
protocol, if one exists. Future research should examine a larger sample of PROSPERO records as 322 
this database matures, as well as examine the discrepancies in primary outcomes reported in the 323 
abstract and full-text of the published systematic reviews.  324 
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Box 1  Classification: Primary outcomes, Meta-analysis results, and Conclusion statements 
 
 
Classification of changes to primary outcomes: 
• New (Inclusion or Addition): the addition of a completely new primary outcome; 
• Exclusion: the omission of a primary outcome in the publication; 
• Upgrade: when a secondary outcome in the protocol was changed to a primary outcome in 
the publication; 
• Downgrade: when a primary outcome in the protocol was changed to a secondary or 
undefined outcome in the publication. 
 
Classification of meta-analysis results: 
• Favourable, statistically significant (i.e. effect in favour of the intervention with p≤ 0.05); 
• Favourable, non-statistically significant; 
• Neutral (effect size between 0.95-1.05 and the confidence interval crosses 1); 
• Unfavourable, statistically significant (i.e. effect in favour of the non-intervention 
comparator with p≤ 0.05);  
• Unfavourable, non-statistically significant. 
 
Categorization of conclusion statements 
• Positive (authors stated that there is evidence of effectiveness); 
• Neutral (no evidence of effectiveness or they reported no opinion); 
• Negative (authors advised against the use of the intervention or it was not recommended); or  
• Indeterminate (authors stated that there is insufficient evidence or that more research is 
required). 
  369 
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FIGURE LEGENDS 370 
Figure 1: Flow of systematic reviews through the study 371 
Figure 2: AMSTAR methodological quality results  372 
Note: NA = not applicable. 373 
Items: 374 
1. A priori design 375 
2. Duplicate selection/DA 376 
3. Literature search 377 
4. Publication status 378 
5. List of studies 379 
6. Study characteristics 380 
7. Quality assessed 381 
8. Quality used 382 
9. Methods appropriate 383 
10. Publication bias assessed 384 
11. Conflicts stated  385 
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Table 1. Characteristics of the 96 included systematic reviews 386 
Characteristic # of systematic reviews (%) 
Publication year  
2011 3 (3.1) 
2012 29 (30.2) 
2013 60 (62.5) 
2014 4 (4.2) 
Total # of studies included  
0-20 70 (72.9) 
21-40 9 (19.8) 
>40 7 (7.3) 
Total # of participants in included studies  
<1000 to 5000 48 (50) 
5001-10,000 5 (5.2) 
10,001-50,000 7 (7.3) 
50,001-100,000 3 (3.1) 
>100,000 2 (2.1) 
Not Reported 31 (32.3) 
Study designs included  
All randomized controlled trials 56 (58.3) 
Mixed study designs* 35 (36.5) 
All observational studies 5 (5.2) 
Meta-analysis conducted  
Yes 67 (69.8) 
No 29 (30.2) 
Funding†  
Stated no funding received 36 (37.5) 
Public funder (e.g., academia, government)  56 (58.4) 
Commercial Organization 4 (4.2) 
Geographic Region‡  
Europe  47 (49) 
North America 20 (20.9) 
South America 11 (11.4) 
Easter Asia 9 (9.3) 
Australia 5 (5.2) 
Southern Asia 2 (2.1) 
Southern Africa 2 (2.1) 
Published protocol in a journal  
Yes 5 (5.2) 
No 91 (94.8) 
Participant population in publication§  
Healthy or presumed healthy 14 (14.6) 
Mixed conditions 11 (11.5) 
Musculoskeletal conditions 10 (10.4) 
Infectious diseases 9 (9.4) 
Present/history of cancer 9 (9.4) 
Pregnancy-related or reproductive conditions 8 (8.3) 
Psychiatric/mental health conditions 7 (7.3) 
Cardiovascular conditions 6 (6.3) 
Respiratory conditions 6 (6.3) 
Autoimmune diseases 3 (3.1) 
Gastrointestinal and abdominal conditions 2 (2.1) 
Genetic diseases 2 (2.1) 
Neurodegenerative/neurological conditions 2 (2.1) 
Oral-related conditions 2 (2.1) 
Urinary conditions 2 (2.1) 
Auditory conditions 1 (1.0) 
Overweight 1 (1.0) 
Type 2 diabetes 1 (1.0) 
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Note: *Mixed could indicate, for example, RCT & quasi-RCT (not necessarily mixed with 387 
observational studies); † Source: Cochrane EPOC Group. Available at: 388 
http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/datacollectionchecklist.pdf; ‡ If 389 
more than one country was listed (n = 8), only the first country’s geographic region is listed here; 390 
§as reported by the review authors.  391 
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Table 2. Number of Primary Outcomes in the Publications 392 
Outcome details # of systematic reviews (%) 
Number explicit per review 
0 37 (38.5) 
1 35 (36.5) 
2 10 (10.4) 
3 6 (6.3) 
4 3 (3.1) 
5 1(1.0) 
6 2 (2.1) 
7 1 (1.0) 
8 1 (1.0) 
Number derived per review 
NA (were explicit) 59 (61.5) 
1 24 (25.0) 
2 6 (6.3) 
3 5 (5.2) 
4 1 (1.0) 
5 0 (0) 
6 1 (1.0) 
Derived Method Used  
NA (were explicit) 59 (61.5) 
Method 1-from title 13 (13.5) 
Method 2-from objectives 9 (9.4) 
Method 3-most serious 15 (15.6) 
Abbreviation: NA = not applicable.  393 
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Table 3. Changes in Primary Outcomes 394 
Change Type # of systematic reviews with ≥1 
change(s) (%)* 
New Primary Outcome(s) 6 (5.9) 
Exclusion of Primary Outcome(s) 6 (5.9) 
Upgrade of Primary Outcome(s) 6 (5.9) 
Downgrade of Primary Outcome(s) 22 (21.8) 
Change in Primary Outcome Definition 6 (5.9) 
Change in Primary Outcome Measure 1 (1.0) 
No Discrepancies 65 (67.7) 
Note: *Does not add up to 100% because some systematic reviews included more than 1 primary 395 
outcome.   396 
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2,426 registered systematic 
reviews of which 343 were 
completed systematic reviews
203 excluded records because 
systematic review was not published
140 potentially 
relevant records 
(completed and published 
systematic reviews)
96 included systematic review 
PROSPERO records
44 excluded records:
• 43 were not a systematic review 
of an intervention
• 1 final report was not published 
in English
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